By Irishexaminer.com,Martin Claffey

Copyright irishexaminer

A Dept of Enterprise spokesperson confirmed received a notification of proposed collective redundancies from Novo Nordisk Production Ireland Limited on September 10. This notification is required when more than 30 redundancies are planned.

Novo Nordisk would not comment on how many redundancies are planned in Ireland, amid reports locally that 115 job cuts are planned. “Out of respect for the employees involved, we will not share additional details about individual sites or areas. This process takes time, and our highest priority is to support our employees,” a Novo Nordisk spokesperson said.

Novo Nordisk competed the purchase of their Athlone manufacturing facility in May 2024 from Alkermes for $91m (€77m). The site was once a production facility for the drugmaker Elan. In 2024, Novo Nordisk was Europe’s most valuable company but the company’s share price has since lost more than $400bn (€340bn) this year, amid intense competition for its weight loss drugs.

“We are announcing a company-wide transformation to simplify our organisation, improve decision-making speed, and reallocate resources towards the company’s growth opportunities in diabetes and obesity,” a spokesperson said on Tuesday. “As part of this change, we are assessing all business areas and regions to simplify structures, reduce duplication, and sharpen focus. These organisational changes will allow Novo Nordisk’s teams to work more efficiently and focus on what matters most: driving innovation and reaching many more patients.”